Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn's Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER Study

被引：0
|
作者：
Feagan, Brian G. [1 ]
Lee, Scott D. [2 ]
van der Woude, C. Janneke [3 ]
Marin-Jimenez, Ignacio [4 ]
Wolf, Douglas C. [5 ]
Schnoy, Elisabeth [6 ]
Salzberg, Bruce [7 ]
Busse, Christopher [8 ]
Nazar, Maciej [9 ]
Langholff, Wayne [10 ]
Gasink, Christopher [8 ]
Baker, Thomas [10 ]
Godwin, Bridget [8 ]
Adedokun, Omoniyi [10 ]
Schreiber, Stefan [11 ]
机构：
[1] Western Univ, London, ON, Canada
[2] Univ Washington, Seattle, WA USA
[3] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[4] Hosp Univ Gregorio Maranon, IiSGM, Rotterdam, Zuid Holland, Netherlands
[5] Atlanta Gastroenterol Associates, Atlanta, GA USA
[6] Univ Hosp Augsburg, Augsburg, Germany
[7] IBD Ctr Atlanta, Atlanta Gastroenterol, Atlanta, GA USA
[8] Janssen Sci Affairs LLC, Horsham, PA USA
[9] Janssen Cilag Polska Sp Zoo, Warsaw, Poland
[10] Janssen Res & Dev LLC, Spring House, PA USA
[11] Univ Hosp Schleswig Holstein, Kiel, Germany
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S842
引用
收藏
页码：S622 / S622
页数：1
相关论文
共 50 条
  • [41] Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn's Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study
    Rosh, Joel R.
    Turner, Dan
    Griffiths, Anne
    Cohen, Stanley A.
    Jacobstein, Douglas
    Adedokun, Omoniyi J.
    Padgett, Lakshmi
    Terry, Natalie A.
    O'Brien, Christopher
    Hyams, Jeffrey S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (11): : 1931 - 1942
  • [42] Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohn's Disease Patients: Results from the IM-UNITI Maintenance Study
    Sands, Bruce
    Gasink, Chris
    Jacobstein, Doug
    Gao, Long Long
    Johanns, Jewel
    Szapary, Philippe
    Colombel, Jean-Frederic
    Targan, Stephan
    Ghosh, Subrata
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S302 - S303
  • [43] Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort
    An, Y. K.
    Lindsay, N.
    Allan, N.
    Khoo, E.
    Fernandes, R.
    Amiss, A.
    Pham, H.
    Wong, K. F.
    Ooi, S. Y.
    Thin, L.
    Lightowler, D.
    Connor, S. J.
    Williams, A. J.
    De Cruz, P.
    Suen, C. Li Wai
    Kariyawasam, V.
    Mitrev, N.
    Ghaly, S.
    Andrews, J. M.
    Christensen, B.
    Sparrow, M. P.
    White, L. S.
    Bryant, R. V.
    Ding, N.
    Leong, R.
    Van Langenberg, D.
    Seltenreich, H.
    Subramaniam, K.
    Radford-Smith, G.
    Begun, J.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 793 - 794
  • [44] Trajectories of response in patients with moderately-to-severely active Crohn's disease treated with mirikizumab or ustekinumab: Post hoc results from the VIVID-1 study
    Schreiber, S. W.
    Clemow, D. B.
    Yu, G.
    Keefer, L. A.
    Ananthakrishnan, A. N.
    D'Haens, G.
    Deepak, P.
    Kocchar, G. S.
    Melmed, G. Y.
    Chen, Y. F.
    Moses, R. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1592 - i1594
  • [45] EFFICACY & SAFETY OF DOSE ADJUSTMENT & DELAYED RESPONSE TO USTEKINUMAB IN MODERATE-SEVERE CROHN'S DISEASE PATIENTS: RESULTS FROM IM-UNITI MAINTENANCE STUDY
    Sands, B.
    Gasink, C.
    Jacobstein, D.
    Gao, L.
    Johanns, J.
    Szapary, P.
    Colombel, J.
    Targan, S.
    Ghosh, S.
    Sandborn, W.
    GUT, 2017, 66 : A23 - A23
  • [46] USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
    Danese, Silvio
    Vermeire, Severine
    D'Haens, Geert
    Panes, Julian
    Dignass, Axel
    Magro, Fernando
    Nazar, Maciej
    Le Bars, Manuela
    Lahaye, Marjolein
    Ni, Lioudmila
    Gaya, Daniel R.
    Peyrin-Biroulet, Laurent
    GASTROENTEROLOGY, 2021, 160 (06) : S409 - S409
  • [47] Pharmacokinetics and Exposure-Response Relationships of Golimumab in Pediatric Patients With Moderate to Severe Ulcerative Colitis: Results From a Multicenter Open Label Study
    Adedokun, Omoniyi J.
    Chan, Daphne
    Padgett, Lakshmi
    Xu, Yan
    Hyams, Jeffrey S.
    Turner, Dan
    Xu, Zhenhua
    Davis, Hugh M.
    Strauss, Rick
    GASTROENTEROLOGY, 2016, 150 (04) : S590 - S590
  • [48] Improved clinical response following a third dose of ustekinumab in psoriasis patients not achieving PASI75 at week 16: results from the phoenix 1 and phoenix 2 trials
    Sobell, J.
    Hamilton, T.
    Reich, K.
    Ho, V.
    Toth, D.
    Yeilding, N.
    Li, S.
    Fakharzadeh, S.
    Korman, N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 20 - 21
  • [49] THE FECAL MICROBIOME AS A TOOL FOR MONITORING AND PREDICTING RESPONSE OUTCOMES IN USTEKINUMAB-TREATED, ANTI-TNFα REFRACTORY CROHN'S DISEASE PATIENTS: RESULTS FROM THE CERTIFI STUDY
    Doherty, Matthew K.
    Koumpouras, Charles
    Telesco, Shannon
    Monast, Calixte S.
    Brodmerkel, Carrie
    Schloss, Patrick D.
    GASTROENTEROLOGY, 2017, 152 (05) : S191 - S191
  • [50] The fecal microbiome as a tool for monitoring and predicting response outcomes in ustekinumab-treated, anti-TNFα refractory Crohn's disease patients: results from the CERTIFI study
    Doherty, M. K.
    Koumpouras, C.
    Telesco, S. E.
    Monast, C.
    Brodmerkel, C.
    Schloss, P. D.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S58 - S58
12345